Balaxi Pharmaceuticals Ltd: Pharma stock under Rs 40 jumps 9.8% on November 21; Do you have it?

On Friday, one of the Top Gainers on NSE, shares of Balaxi Pharmaceuticals Ltd, jumped 9.80 per cent to an Intraday high of Rs 39.49 per share from its previous closing of Rs 35.98 per share, with 2.5 lakh shares changing hands. The stock’s 52-week high is Rs 85.58 per share and its 52-week low is Rs 35.67 per share.

Balaxi Pharmaceuticals Ltd is an IPR-based pharmaceutical company that focuses on the production, stocking, selling, and supply of both branded and generic medicines. With a substantial portfolio of 610 pharmaceutical product registrations, Balaxi offers a diverse range of products, including tablets, injectables, liquids, and capsules, sourced from WHO-GMP-certified contract manufacturers located in India, China and Portugal. The company has a market cap of over Rs 200 crore and the shares of the company have a PE of 12x whereas the industry PE is 32x.

In its Quarterly Results (Q2FY26), the company reported net sales of Rs 56.18 crore and a net profit of Rs 0.21 crore while in its half-yearly results (H1FY26), the company reported net sales of Rs 126.92 crore and a net profit of Rs 0.50 crore. Looking at its annual results (FY25), the net sales increased by 22 per cent to Rs 293 crore compared to FY24. The company reported a net profit of Rs 25 crore in FY25 compared to a net loss of Rs 2 crore in FY24, an increase of 1,350 per cent.

Balaxi Pharmaceuticals Limited announced a significant strategic investment and a milestone achievement in its manufacturing capabilities. Pursuant to Regulation 30 of the SEBI Listing Regulations, the company has approved an equity infusion of up to USD 4 million in its wholly-owned Dubai subsidiary, Balaxi Global FZCO, to support its operational and business expansion requirements. Furthermore, the Board of Directors was updated on the substantial progress of the company's first pharmaceutical formulation plant located in Jadcherla, Hyderabad. The setup of the facility is complete, the test manufacturing license has been obtained, and critical steps like water system validation and vendor qualification have been finalised, leading to the successful production of initial test batches, including Paracetamol 500 mg and Piroxicam 20 mg, which are now undergoing stability studies.

Disclaimer: The article is for informational purposes only and not investment advice.